Sarepta Therapeutics appoints Michael Severino, former Tessera CEO, as new chief executive
Sarepta Therapeutics announced that Michael Severino will become its chief executive, effective Tuesday. Severino previously led Tessera Therapeutics.
He replaces Doug Ingram, who said he will retire after nearly a decade at the helm. Under Ingram, Sarepta secured approvals for three Duchenne muscular dystrophy treatments.
The company has faced scrutiny over the efficacy and safety of its gene therapy and its share price has fallen sharply since early 2025.
The leadership change comes as Sarepta confronts growing competition in the DMD market and ongoing regulatory challenges.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive”
read at STAT ↗
comments(0)
5-min edit window · permanent after that